Class I · Recall · initiated April 3, 2026 · Ongoing
Addall XR Shot recalled: liquid supplement contained DMAA, phenylethylamine and phenibut
ZMB Enterprises recalled its Addall XR Shot, a liquid dietary supplement sold on its website, because the product contains 1,4-DMAA, phenylethylamine and phenibut, none of which are permitted dietary ingredients. Initiated in April, the record was published in September.
The record
- Firm
- ZMB Enterprises, Carlsbad, CA
- Product
- Addall XR Shot 1 single bottle, 2 fl. oz., liquid dietary supplement
- Reason, as filed
- “The product contains 1,4-DMAA, Phenylethylamine and Phenibut.”
- Classification
- Class I (Class I: reasonable probability of serious health consequences or death)
- Recall number
- H-1263-2026
- Initiated
- April 3, 2026
- Posted by FDA
- September 2, 2026
- Status
- Ongoing · Voluntary: Firm initiated
- Quantity
- unknown
- Distribution
- The firm markets their products online via their website addallxr.com
Verify: search any recall number above in FDA's enforcement report database.
Why it happened, in plain English
This is not a contamination recall; it is a formulation recall. The filed reason states the product contains three substances: 1,4-DMAA, a stimulant FDA has said is not a legal dietary ingredient; phenylethylamine; and phenibut, a prescription anxiolytic in some countries with a withdrawal profile. A product containing these is not a dietary supplement under the law, whatever the label says.
Note the dates. The recall was initiated April 3 and reached FDA’s public enforcement report on September 2, five months later. Marketplace listings and consumer-facing notices often move faster than the enforcement report.
Who else should care
Brands in the “focus,” energy, nootropic and pre-workout categories, and the contract manufacturers who fill them. FDA buys and tests products in these categories continuously, and its list of undeclared or prohibited ingredients is public.
Check: every ingredient on your formula against FDA’s dietary supplement ingredient advisory list, and confirm your contract manufacturer does the same for client-supplied premixes.
Written 2026-09-08. Analysis is editorial; the record above is FDA's.